FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062912758> ?p ?o ?g. }

• W2062912758 abstract "Artemisinin-based combination therapy (ACT) is recommended as a means of prolonging the effectiveness of first-line malaria treatment regimens. Different brands of mefloquine (MQ) have been reported to be non-bioequivalent; this could result in sub-therapeutic levels of mefloquine with decreased efficacy. In 2002, mefloquine-artesunate (MQ-AS) combination therapy was adopted as the first-line treatment for uncomplicated Plasmodium falciparum malaria in the Amazon region of Peru. Although MQ resistance has yet to be reported from the Peruvian Amazon, it has been reported from other countries in the Amazon Region. Therefore, continuous monitoring is warranted to ensure that the first-line therapy remains efficacious. This study examines the in vivo efficacy and pharmacokinetic parameters through Day 56 of three commercial formulations of MQ (Lariam®, Mephaquin®, and Mefloquina-AC® Farma) given in combination with artesunate. Thirty-nine non-pregnant adults with P. falciparum mono-infection were randomly assigned to receive artesunate in combination with either (1) Lariam, (2) Mephaquin, or (3) Mefloquina AC. Patients were assessed on Day 0 (with blood samples for pharmacokinetics at 0, 2, 4, and 8 hours), 1, 2, 3, 7, and then weekly until day 56. Clinical and parasitological outcomes were based on the standardized WHO protocol. Whole blood mefloquine concentrations were determined by high-performance liquid chromatography and pharmacokinetic parameters were determined using non-compartmental analysis of concentration versus time data. By day 3, all patients had cleared parasitaemia except for one patient in the AC Farma arm; this patient cleared by day 4. No recurrences of parasitaemia were seen in any of the 34 patients. All three MQ formulations had a terminal half-life of 14–15 days and time to maximum plasma concentration of 45–52 hours. The maximal concentration (Cmax) and interquartile range was 2,820 ng/ml (2,614–3,108) for Lariam, 2,500 ng/ml (2,363–2,713) for Mephaquin, and 2,750 ng/ml (2,550–3,000) for Mefloquina AC Farma. The pharmacokinetics of the three formulations were generally similar, with the exception of the Cmax of Mephaquin which was significantly different to that of Lariam (p = 0.04). All three formulations had similar pharmacokinetics; in addition, the pharmacokinetics seen in this Peruvian population were similar to reports from other ethnic groups. All patients rapidly cleared their parasitaemia with no evidence of recrudescence by Day 56. Continued surveillance is needed to ensure that patients continue to receive optimal therapy." @default.
• W2062912758 created "2016-06-24" @default.
• W2062912758 creator A5003637667 @default.
• W2062912758 creator A5007468909 @default.
• W2062912758 creator A5013008946 @default.
• W2062912758 creator A5014092989 @default.
• W2062912758 creator A5014768914 @default.
• W2062912758 creator A5029028573 @default.
• W2062912758 creator A5042474892 @default.
• W2062912758 creator A5071022493 @default.
• W2062912758 creator A5078792522 @default.
• W2062912758 creator A5084708206 @default.
• W2062912758 date "2009-04-09" @default.
• W2062912758 modified "2023-10-18" @default.
• W2062912758 title "Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria" @default.
• W2062912758 cites W1599232107 @default.
• W2062912758 cites W1903801641 @default.
• W2062912758 cites W1965960128 @default.
• W2062912758 cites W1967304327 @default.
• W2062912758 cites W1999228678 @default.
• W2062912758 cites W2005816578 @default.
• W2062912758 cites W2009377141 @default.
• W2062912758 cites W2014790142 @default.
• W2062912758 cites W2025486518 @default.
• W2062912758 cites W2027313042 @default.
• W2062912758 cites W2038387558 @default.
• W2062912758 cites W2040209173 @default.
• W2062912758 cites W2074080264 @default.
• W2062912758 cites W2076688927 @default.
• W2062912758 cites W2087464705 @default.
• W2062912758 cites W2090797370 @default.
• W2062912758 cites W2101762246 @default.
• W2062912758 cites W2111813303 @default.
• W2062912758 cites W2116350812 @default.
• W2062912758 cites W2116677110 @default.
• W2062912758 cites W2146162023 @default.
• W2062912758 cites W2148461709 @default.
• W2062912758 cites W2153266724 @default.
• W2062912758 cites W2154810899 @default.
• W2062912758 cites W2162445884 @default.
• W2062912758 cites W2166664177 @default.
• W2062912758 cites W2167433327 @default.
• W2062912758 cites W4361868505 @default.
• W2062912758 doi "https://doi.org/10.1186/1475-2875-8-58" @default.
• W2062912758 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2674465" @default.
• W2062912758 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19358697" @default.
• W2062912758 hasPublicationYear "2009" @default.
• W2062912758 type Work @default.
• W2062912758 sameAs 2062912758 @default.
• W2062912758 citedByCount "34" @default.
• W2062912758 countsByYear W20629127582012 @default.
• W2062912758 countsByYear W20629127582013 @default.
• W2062912758 countsByYear W20629127582014 @default.
• W2062912758 countsByYear W20629127582015 @default.
• W2062912758 countsByYear W20629127582016 @default.
• W2062912758 countsByYear W20629127582017 @default.
• W2062912758 countsByYear W20629127582018 @default.
• W2062912758 countsByYear W20629127582019 @default.
• W2062912758 countsByYear W20629127582020 @default.
• W2062912758 countsByYear W20629127582021 @default.
• W2062912758 countsByYear W20629127582022 @default.
• W2062912758 countsByYear W20629127582023 @default.
• W2062912758 crossrefType "journal-article" @default.
• W2062912758 hasAuthorship W2062912758A5003637667 @default.
• W2062912758 hasAuthorship W2062912758A5007468909 @default.
• W2062912758 hasAuthorship W2062912758A5013008946 @default.
• W2062912758 hasAuthorship W2062912758A5014092989 @default.
• W2062912758 hasAuthorship W2062912758A5014768914 @default.
• W2062912758 hasAuthorship W2062912758A5029028573 @default.
• W2062912758 hasAuthorship W2062912758A5042474892 @default.
• W2062912758 hasAuthorship W2062912758A5071022493 @default.
• W2062912758 hasAuthorship W2062912758A5078792522 @default.
• W2062912758 hasAuthorship W2062912758A5084708206 @default.
• W2062912758 hasBestOaLocation W20629127581 @default.
• W2062912758 hasConcept C112705442 @default.
• W2062912758 hasConcept C126322002 @default.
• W2062912758 hasConcept C203014093 @default.
• W2062912758 hasConcept C2776120307 @default.
• W2062912758 hasConcept C2776999253 @default.
• W2062912758 hasConcept C2777199930 @default.
• W2062912758 hasConcept C2778048844 @default.
• W2062912758 hasConcept C2778059366 @default.
• W2062912758 hasConcept C2778371730 @default.
• W2062912758 hasConcept C71924100 @default.
• W2062912758 hasConcept C98274493 @default.
• W2062912758 hasConceptScore W2062912758C112705442 @default.
• W2062912758 hasConceptScore W2062912758C126322002 @default.
• W2062912758 hasConceptScore W2062912758C203014093 @default.
• W2062912758 hasConceptScore W2062912758C2776120307 @default.
• W2062912758 hasConceptScore W2062912758C2776999253 @default.
• W2062912758 hasConceptScore W2062912758C2777199930 @default.
• W2062912758 hasConceptScore W2062912758C2778048844 @default.
• W2062912758 hasConceptScore W2062912758C2778059366 @default.
• W2062912758 hasConceptScore W2062912758C2778371730 @default.
• W2062912758 hasConceptScore W2062912758C71924100 @default.
• W2062912758 hasConceptScore W2062912758C98274493 @default.
• W2062912758 hasIssue "1" @default.
• W2062912758 hasLocation W20629127581 @default.
• W2062912758 hasLocation W20629127582 @default.
• W2062912758 hasLocation W20629127583 @default.

• next